Allografts: expanding the surgeon's armamentarium.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: The authors NA, VE, AP, JB are employees of the German Institute for Cell and Tissue Replacement (DIZG gemeinnützige GmbH), a non-profit provider of sterile allografts. AP is the head of the Charité tissue bank also a provider of sterile allografts.TV and CP have no conflict of interest to declare. 5. Crit Rev Oral Biol Med. 1997;8(2):201-16. doi: 10.1177/10454411970080020701. Graft-vs.-host disease. Woo SB(1), Lee SJ, Schubert MM. Author information: (1)Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. Bone marrow transplantation (BMT) is the treatment of choice for many leukemias, lymphomas, bone marrow failure syndromes, and immunodeficiency disorders, and is the primary and salvage therapy for many solid malignancies. With the establishment of national and international marrow banks, unrelated allogeneic BMT is being performed with increasing frequency. Graft-vs.-host disease (GVHD) remains a major complication of allogeneic BMT, occurring in 25% to 70% of patients despite GVHD prophylaxis, with the skin, gastro-intestinal tract, and liver as primary target organs. Oral findings are seen in both acute and chronic GVHD. In acute GVHD, the oral lesions are often painful, erythematous, ulcerative, and desquamative. In chronic GVHD, they are lichenoid with associated erythema and ulcerations; additionally, they may be associated with a sicca syndrome characterized by xerostomia and progressive salivary gland atrophy. General principles of BMT are discussed, as are systemic and local therapeutic options for oral GVHD. DOI: 10.1177/10454411970080020701